Cost effectiveness of prophylaxis for opportunistic infections in AIDS: An overview and methodological discussion

PharmacoEconomics

Volumn 14, Issue 2, 1998, Pages 165-173

  Freedberg, Kenneth A ^a,b,d   Paltiel, A David ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ATOVAQUONE; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; GANCICLOVIR; PENTAMIDINE; PNEUMOCOCCUS VACCINE; RIFABUTIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC PROPHYLAXIS; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CYTOMEGALOVIRUS INFECTION; DRUG COST; HUMAN; MYCOBACTERIOSIS; MYCOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

EID: 0031824882     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814020-00005     Document Type: Review

References (48)

1. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997; 46-RR12: 1-46
2. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA 1997; 277: 1962-9
3. National ADAP monitoring project: interim technical report. Washington, DC: National Alliance of State and Territorial AIDS Directors and the AIDS Treatment Data Network, 1997
4. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995; 21 Suppl. 1: 32-43
5. Drug topics red book. Montvale (NJ): Medical Economics, 1996
6. Seage GR, Landers S, Barry MA, et al. Medical care costs of AIDS in Massachusetts. JAMA 1986; 256: 3107-9
7. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep 1987; 102: 5-17
8. Hellinger FJ. Forecasts of the costs of medical care for persons with HIV: 1992-1995. Inquiry 1992; 29 (3): 356-65
9. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993; 270: 474-8
10. Moore RD, Chaisson RE. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immune Defic Syndr 1997; 14: 223-31
11. Gable CB, Tierce JC, Simison D, et al. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr 1996; 12: 413-20
12. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259: 1185-9
13. Freedberg KA, Tosteson ANA, Cohen CJ, et al. Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/ul: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 1991; 4: 521-31
14. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992; 327: 1842-8
15. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA 1991; 266: 820-4
16. Freedberg KA, Hardy WD, Holzman RS, et al. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Med Decis Making 1996; 16: 29-35
17. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996; 335: 392-8
18. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384-90
19. Bozzette SA, Finklestein DM, Spector SA, et al. A randomised trial of 3 antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 693-9
20. Moore RM, Chaisson RE. Cost-effectiveness analysis for Mycobacterium avium complex disease. Am J Med 1997; 102: 50-5
21. Freedberg KA, Cohen CJ, Barber TW. Preventing Mycobacterium avium complex infection in patients with AIDS: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 1997; 15: 275-82
22. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 700-5
23. Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of preventing fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making 1997; 17: 373-81
24. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganiclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996; 334: 1491-7
25. Moore RD, Chaisson RE. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr 1997; 16: 15-21
26. Paltiel AD, Freedberg KA. Cost-effectiveness of preventing CMV disease in AIDS patients. Interfaces. In press
27. Rose DN, Sacks HS, Lan V. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS 1997; 11: 883-7
28. Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis. Am J Med 1993; 942: 160-8
29. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329: 828-33
30. Benson CA, Cohn DL, Williams P, the ACTG 196/CPCRA 009 Study Team, et al. A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin (CLA) vs. rifabutin (RBT) vs. CLA+RBT prevention of Mycobacterium avium Complex (MAC) disease in HIV+ patients with CD4 counts < 100 cells/ul. Third Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28-Feb I; Washington, DC: 91
31. Freedberg KA, Scharfstein JA, Seage GR, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279: 130-6
32. Nightingale SD, Cal SX, Peterson DM, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992; 6: 191-4
33. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. Ann Intern Med 1997; 126: 689-96
34. Brosgart CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals: Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 1998; 12(3): 269-77
35. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Preface to the 1997 USPHS/IDS guidelines for prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1997; 25 Suppl. 3: S299-312
36. Hammer SM, Squires KE, Hughes MD, et al. A control led trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33
37. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. Pharmacoeconomics 1996; 10 (2): 109-13
38. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-90
39. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996; 348: 283-91
40. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33
41. Moore RD, Keruly JC, Chaisson RE. Decline in CMV and other opportunistic disease with combination antiretroviral therapy [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago: 184
42. Kaplan JE, Masur H, Jaffe HW, et al. Preventing opportunistic infections in persons infected with HIV: guidelines [editorial]. JAMA 1997; 278 (4): 337-8
43. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effort of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA 1997; 277 (19): 1519-20
44. AIDS Clinical Trial Group Protocol 362. A randomized, placebo controlled trial to determine the efficacy of azithromycin prophylaxis for the primary prevention of Mycobacterium avium complex (MAC) disease and other infections in subjects who have achieved an increase in CD4 cells on antiretroviral therapy. Version 1.0. Washington, DC: National Institute of Allergy and Infectious Diseases, 1997
45. Gold MR, Siegel JE, Russel LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
46. Owens DK, Nease RF, Harris RA. Use of cost-effectiveness and value of information analyses to customize guidelines for specific clinical practice settings [abstract]. Med Decis Making 1993; 13: 395
47. Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research policy analysis. Health Psychol 1981; 1: 61-80
48. Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81